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Abstract
Introduction: Guidelines recommend that two blood cultures be performed in patients with febrile urinary tract
infection (UTI), to detect bacteremia and help diagnose urosepsis. The usefulness and cost-effectiveness of this
practice have been criticized. This study aimed to evaluate clinical characteristics and the biomarker procalcitonin
(PCT) as an aid in predicting bacteremia.
Methods: A prospective observational multicenter cohort study included consecutive adults with febrile UTI in 35
primary care units and 8 emergency departments of 7 regional hospitals. Clinical and microbiological data were
collected and PCT and time to positivity (TTP) of blood culture were measured.
Results: Of 581 evaluable patients, 136 (23%) had bacteremia. The median age was 66 years (interquartile range 46
to 78 years) and 219 (38%) were male. We evaluated three different models: a clinical model including seven bed-
side characteristics, the clinical model plus PCT, and a PCT only model. The diagnostic abilities of these models as
reflected by area under the curve of the receiver operating characteristic were 0.71 (95% confidence interval (CI):
0.66 to 0.76), 0.79 (95% CI: 0.75 to 0.83) and 0.73 (95% CI: 0.68 to 0.77) respectively. Calculating corresponding
sensitivity and specificity for the presence of bacteremia after each step of adding a significant predictor in the
model yielded that the PCT > 0.25 μg/l only model had the best diagnostic performance (sensitivity 0.95; 95% CI:
0.89 to 0.98, specificity 0.50; 95% CI: 0.46 to 0.55). Using PCT as a single decision tool, this would result in 40%
fewer blood cultures being taken, while still identifying 94 to 99% of patients with bacteremia.
The TTP of E. coli positive blood cultures was linearly correlated with the PCT log value; the higher the PCT the
shorter the TTP (R
2 = 0.278, P = 0.007).
Conclusions: PCT accurately predicts the presence of bacteremia and bacterial load in patients with febrile UTI.
This may be a helpful biomarker to limit use of blood culture resources.
Introduction
Urinary tract infection (UTI) is one of the most com-
mon infectious diseases. Fever in UTI typically repre-
sents the presence of acute pyelonephritis but it may
also reflect prostatitis and/or the urosepsis syndrome
[1,2]. Patients with febrile UTI generally present with
mild illness in primary care but may rapidly develop a
life-threatening condition, progressing into septic shock
and multiple organ failure. The overall mortality rate of
pyelonephritis is approximately 0.3%, but in bacteremic
patients it can be as high as 7.5% to 30% [3,4]. In addi-
tion, bacteremia in UTI is associated with prolonged
hospitalization and higher complication rates [5-7].
Given this spectrum of disease, clinicians are vigilant to
identify bacteremia at a patient’s presentation.
The incidence of bacteremia in patients with acute
pyelonephritis has been reported to be roughly 20%
[8-10]. Several studies have been conducted to identify
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UTI [6,7,11,12]. However, no single clinical model has
been used in practice because of its poor value in pre-
dicting bacteremia. The gold standard for detection of
bacteremia remains the performance of at least two
blood cultures to achieve sufficient sensitivity [13].
There are, however, practical limitations. First of all, it
takes at least 24 to 48 hours to attain the culture
result. Secondly, there may be a false positive result as
contamination rates of up to 7% have been reported
[14]. Furthermore, the implementation of the surviving
sepsis campaign, which recommends the immediate
initiation of broad-spectrum antibiotic therapy once
septicemia is suspected, leads to an increase in the
performance of blood cultures with lower yield, likely
reflecting the obtainment of additional cultures after
initiation of antibiotics [15,16]. Therefore, there is a
need for strategies that guide clinicians and help
reduce avoidable blood cultures and, by consequence,
medical costs.
The biomarker procalcitonin (PCT) is a marker of sys-
temic inflammation and thus it may help to predict bac-
teremia [17,18]. The aim of this study was to assess
clinical characteristics and the PCT value to predict bac-
teremia in patients with febrile UTI.
Materials and methods
Study design and setting
We conducted a prospective observational multicenter
cohort study. Eight emergency departments (ED) of 7
hospitals and 35 affiliating primary health care centers,
serving one single area of the Netherlands, participated.
Consecutive patients who presented with a diagnosis of
febrile UTI, were considered for enrollment in the
study. Recruitment took place from January 2004
through November 2008 but each centre started at dif-
ferent time points. The study was approved by the local
ethics committees and all included patients gave written
informed consent.
Inclusion and exclusion criteria
Inclusion criteria were: age of 18 years or above, fever
(defined as an tympanic temperature ≥38.0°C or a his-
tory of fever and chills within 24 hours before presenta-
tion), at least one symptom of UTI (dysuria, frequency,
urgency, perineal pain, flank pain or costovertebral ten-
derness) and a positive nitrite dipstick test or leukocy-
turia as defined by a positive leukocyte esterase dipstick
t e s to rt h ep r e s e n c eo fm o r et h a nf i v el e u k o c y t e sp e r
high-power field in a centrifuged sediment. Exclusion
criteria were current treatment for urolithiasis or hydro-
nephrosis, pregnancy, hemo- or peritoneal dialysis, a his-
tory of kidney transplantation or known presence of
polycystic kidney disease.
Procedures and definitions
Clinical data and laboratory values were collected by
qualified research nurses or the clinical investigators
(CvN, TNB). Baseline data were collected within 24
hours of enrolment by a standardized questionnaire of
the patient and reviewing the medical record. All
patients were empirically treated with antibiotics accord-
ing to local policy (oral ciprofloxacin 500 mg twice daily
for outpatients and cefuroxim ± gentamicin intrave-
nously for inpatients). Based on the culture results, hos-
pitalized patients were subsequently switched to oral
antibiotic treatment (first choice ciprofloxacin).
Blood cultures were obtained before commencement
of antimicrobial therapy and were analyzed using local
standard microbiological methods. At least two sets of
10 mL blood samples were taken and inoculated into
aerobic bottles, which were incubated into an automated
continuous monitoring system. In the Leiden University
Medical Center (LUMC), the BACTEC 9240 (Becton
Dickinson Diagnostic Instrument Systems, Sparks, MD,
USA) was used, which monitors CO2 production every
10 minutes by means of a fluorescent signal. The bottles
were loaded in the automated system once received at
t h el a b o r a t o r y .T h et i m et op o s i t i v i t y( T T P ) ,d e f i n e da s
the time from the start of incubation to the start of the
alert signal (as documented by the monitoring system),
was recorded for each bottle of positive blood cultures.
When multiple cultures were positive, the shortest TTP
was selected for analysis. TTP was analyzed for E. coli
positive blood cultures and confined to results in one
center, the LUMC, as the TTP depends on the microor-
ganism and the logistics of blood culture performance
(for example, transport time from blood culture obtain-
ment to incubator) [19].
Clean midstream-catch urine cultures were obtained
before starting antimicrobial therapy and were analyzed
using local standard microbiological methods. In case of
a urinary catheter, the urine sample was collected from
the port of the catheter. A positive urine culture was
defined as bacterial growth over 10
3 CFU/ml urine or a
bacterial monoculture over 10
2 CFU/ml urine in the
presence of pyuria [20]. Urine cultures revealing growth
of two or more different bacterial species reflecting
mixed skin or gut flora were considered to indicate con-
tamination [20].
Plasma EDTA blood samples were collected, centri-
fuged and stored at -80°C within two hours of patient
enrolment. PCT levels were measured after the comple-
tion of all study enrolments, using a Time Resolved
Amplified Cryptate Emission technology assay (TRACE®,
Kryptor compact, PCTsensitive; Brahms AG; Hennigs-
dorf, Germany).
Bacteremia was defined as growth of any pathogen in
the blood culture. The isolation of coagulase-negative
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indicate contamination and thus absence of bacteremia.
Statistical analysis
Descriptive analysis included means or percentages with
95% confidence intervals (CIs) or medians and ranges,
as appropriate. Missing values of categorical variables
were considered to indicate the absence of that charac-
teristic. This was applied for shaking chills (n = 66) and
costovertebral tenderness (n = 18). Univariate analysis
was performed using the Student’s t-test or Mann-Whit-
ney U test for continuous variables and Chi-square tests
for categorical variables. Covariates found to be asso-
ciated with bacteremia on univariate analysis at a level
of significance P < 0.2 were eligible for inclusion in a
multivariate logistic regression model using a backward
selection procedure [21]. Measures for association were
expressed as odds ratios (ORs) for disease with their
95% CIs for categorical variables. We tested the follow-
ing three models: 1). A clinical model including clinical
variables only; 2). A clinical model added with the PCT
value; 3). A model based on PCT only. The predicted
probabilities of bacteremia (Pbac)i na n yp a t i e n tf o rt h e
different models were calculated by using the following
regression equation: ln (Pbac /(1- Pbac)) = intercept + b-
coefficient * variable, where the intercept and b-coeffi-
cient are obtained from logistic regression analysis. We
constructed receiver operating characteristic (ROC)-
curves for the different models using Pbac as the test
variable and bacteremia (yes/no) as state variable. The
discriminative power and the diagnostic performance of
the prediction models were compared by calculating the
area under the curve (AUC) of the ROC-curve and by
Nagelkerke’sR
2. In addition, for the clinical models,
based on the b-coefficient, points were assigned for each
predictor and different cutoff values were used to calcu-
late corresponding sensitivity, specificity, positive and
negative predictive values (PPV, NPV) and likelihood
ratios for predicting bacteremia were calculated. For
PCT, different cutoff values were tested, according to
the instructions by the manufacturer for diagnosis of
bacterial sepsis or lower respiratory tract infection; the
cutoff value corresponding with a sensitivity of 95% and
highest specificity was chosen for further analysis. A P-
value < 0.05 was considered indicative for statistical sig-
nificance. SPSS software (SPSS Inc., Chicago, Ill, USA;
version 17.0) was used for statistical analysis.
Results
Patient characteristics and microbiological results
Of 728 patients screened for eligibility, 642 met the
inclusion criteria and were included in the study of
which 581 were evaluable with concurrent blood cul-
tures and PCT measurements at baseline. Patients
excluded from analysis because of missing blood culture
or PCT value, were similar with respect to demo-
graphics and clinical features. The majority (75%) pre-
sented at EDs. The median age was 66 years, 38% were
men and 52% had co-existing illnesses. Details of the
baseline characteristics are listed in Table 1.
Bacteremia was present in 131 (23%) patients: Escheri-
chia coli, n = 104, (79%); Klebsiella spp., n =6 ,( 5 % ) ;
Proteus spp., n = 5 (4%), Pseudomonas aeroginosa, n =3
(2%); Staphylococcus aureus, n =2( 2 % ) ;Enterococcus
spp., n =2( 2 % ) ;a n do t h e r ,n = 9 (7%). Only sixteen
patients (3%) had coagulase-negative staphylococci in
their blood culture; this was considered contamination.
Bacteremic patients were significantly older, they signifi-
cantly had more diabetes mellitus, shaking chills, or
were pretreated for UTI; costovertebral tenderness was
significantly less frequently present. On physical exami-
nation bacteremic patients more frequently had altered
mental status, and they significantly had higher tempera-
ture and heart rate (Table 1).
U r i n ec u l t u r e sw e r ed o n ei n5 5 9( 9 6 % )p a t i e n t sa n d
revealed the following: E. coli, n = 319 (57%); Klebsiella
spp., n = 25 (4%); Pseudomonas aeroginosa, n = 14 (3%);
Proteus spp., n =1 2( 2 % ) ;Enterococcus spp., n =1 0
(2%); Staphylococcus spp., n = 12 (2%); other uropatho-
gen, n = 21 (3%); contaminated, n = 77 (14%) and nega-
tive urine culture, n =7 1( 1 3 % ) .I nt h o s ep a t i e n t so f
whom no definite uropathogen was isolated, 69% had
antibiotic UTI treatment during obtainment of the urine
culture sample.
Results of con- and discordant blood and urine cul-
tures have been described previously [22].
Procalcitonin and microbiological outcome
The AUC of the ROC-curve of PCT diagnosing bactere-
mia was 0.81 (95% CI: 0.77 to 0.85) indicating good dis-
criminative power (Figure 1). The corresponding
sensitivity, specificity, NPV, PPV and likelihood ratios of
different PCT cutoff values are also outlined in Figure 1.
A cutoff value >0.25 μg/l had a sensitivity of 95% and
was chosen for further analysis in prediction modeling.
As the predictive value of PCT might have been influ-
enced by the antibiotic treatment at the time of presen-
tation in 29% of the patients, the analysis was also done
separately. In patients on active antibiotic UTI treat-
ment, bacteremia was present in 29% of the cases com-
pared to 20% in those without antibiotic treatment.
Corresponding AUC of the ROC-curve were 0.83 (95%
CI: 0.76 to 0.89) and 0.80 (95% CI: 0.75 to 0.85), respec-
tively, indicating that antibiotic treatment did not alter
the predictive value of PCT with respect to bacteremia.
As undetectable PCT levels may be indicative of
absence of bacterial infection we additionally tested
whether a PCT value <0.06 μg/l was correlated with a
van Nieuwkoop et al. Critical Care 2010, 14:R206
http://ccforum.com/content/14/6/R206
Page 3 of 9Table 1 Baseline characteristics of 581 patients presenting with febrile UTI.
Characteristic at presentation All patients
n = 581
Non-bacteremic
n = 450
Bacteremic
n = 131
P
Demographics
Age, years, median (IQR) 66 (46 to 78) 63 (42 to 77) 74 (60 to 84) <0.001
Male sex 219 (38) 163 (36) 56 (43) 0.175
Nursing home residency 29 (5) 20 (4) 9 (7) 0.262
Co-morbidity
Any 301 (52) 226 (50) 75 (57) 0.156
Diabetes mellitus 96 (17) 65 (14) 31 (24) 0.012
Malignancy
a 63 (11) 44 (10) 19 (15) 0.126
Urinary catheter
b 45 (8) 30 (7) 15 (12) 0.093
Urinary tract disorder
c 144 (25) 110 (24) 34 (26) 0.725
Immunocompromised 87 (15) 68 (15) 19 (15) 0.864
History, Signs and Symptoms
Antibiotic UTI treatment
d 167 (29) 119 (26) 48 (37) 0.023
Fever duration, hours, median (IQR)
e 24 (12 to 53) 24 (12 to 48) 24 (12 to 72) 0.791
Altered mental status 46 (8) 27 (6) 19 (15) 0.002
Shaking chills 320 (55) 236 (52) 84 (64) 0.018
Costovertebral tenderness 352 (61) 283 (63) 69 (53) 0.035
Temperature, °C, mean ± SD 38.6 ± 1.05 38.5 ± 1.06 38.8 ± 0.99 0.001
MAP, mmHg, mean ± SD, 101 ± 17 102 ± 17 100 ± 19 0.479
HR, beats/minute, mean ± SD 93 ± 18 91 ± 17 98 ± 20 <0.001
PCT, μg/L, median (IQR) 0.41 (0.13 to 1.68) 0.25 (0.10 to 0.90) 2.29 (0.72 to 9.07) <0.001
Data are presented as n (%) unless otherwise stated. IQR, interquartile range; SD, standard deviation; MAP, mean arterial pressure; HR, heart rate; PCT,
procalcitonin.
a Defined as any cancer except basal- or squamous-cell cancer of the skin that was active within the previous year.
b Indwelling urethral catheter (n
= 36), supra-pubic catheter (n = 7), intermittent urethral self-catherization (n = 2).
c Defined as the presence of any functional or anatomical abnormality of the
urinary tract.
d Present oral antibiotic treatment for non-febrile UTI (that is, fever developed during UTI treatment).
e Missing value in 81 patients.
Figure 1 Predictive value of procalcitonin (PCT) level for the diagnosis of bacteremia in 581 adults presenting with febrile urinary
tract. AUC, area under curve; ROC, receiver operating characteristic; NPV, negative predictive value; PPV, positive predictive value; LR+, positive
likelihood ratio; LR-, negative likelihood ratio.
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associated with a lower rate of negative urine cultures,
11% versus 13% for PCT ≥ 0.06 μg/l, but this difference
was not statistically significant (OR 0.8; 95% CI: 0.3 to
2.2, P = 0.821).
Predictors of bacteremia
Clinical variables that were found to have an association
with the presence of bacteremia with a P-value < 0.2
were entered as covariates into a multivariate logistic
regression model. Then PCT > 0.25 μg/l was added as a
variable in a second model and finally a univariate model
of PCT > 0.25 μg/l was tested. This resulted in three dif-
ferent models (model 1, 2 and 3 respectively) as shown in
Table 2. Older age, higher temperature and heart rate
were significantly associated with bacteremia in the clini-
cal model 1. When PCT was added to this clinical model
(model 2), PCT appeared to be the strongest predictor
(OR 14.7) for bacteremia, besides the significant clinical
predictors temperature >38.6°C (OR 1.7) and diabetes
mellitus (OR 1.8). The discriminative ability of model 2
with respect to Nagelkerke’sR
2 was much better than the
clinical model 1 (0.293 vs 0.145) but comparable with
model 3 based on PCT only (0.252).
Diagnostic value of prediction models
For each model we calculated the probability of bactere-
mia (Pbac) for every individual patient with the equation
a sd e s c r i b e da b o v ea n dc o m p a r e dt h ed i s c r i m i n a t i v e
power of each model by constructing ROC-curves.
Model 1, 2 and 3 had an AUC of ROC of 0.71 (95% CI:
0.66 to 0.76), 0.79 (95% CI: 0.75 to 0.83) and 0.73 (95%
CI: 0.67 to 0.77), respectively.
In addition, we evaluated the diagnostic performance
of each model in detecting bacteremia by measuring
sensitivity, specificity, NPV, PPV and likelihood ratios.
For model 1 and 2 we started with the most significant
clinical predictor as indicated by the lowest P-value
out of the multivariable analysis (Table 2) and then we
stepwise added the next significant clinical predictor
with increasing order of P-values. For each step, the
corresponding sensitivity, specificity, NPV, PPV and
likelihood ratios were calculated. In addition, the same
was done in model 2 starting with PCT and then add-
ing the clinical predictors. The results of this analysis
are outlined in Table 3. Only model 2 and 3 including
PCT as a predictor had a NPV >95% but model 3
(PCT > 0.25 μg/l only) had a better PPV. Thus the dis-
criminative ability of PCT alone is better than PCT
plus clinical predictors.
Procalcitonin and time to positivity of blood culture
The TTP was available in 25 of 26 E. coli positive blood
cultures. The mean TTP was 11.6 hours (range 1.3 to
31.4 hrs). Plotting TTP with the log value of PCT
resulted in a significant linear correlation (R
2 =0 . 2 7 8 ,P
= 0.007), being the higher the PCT the shorter the TTP
(Figure 2).
Potential cost-savings of blood culture resources
We calculated potential cost-savings assuming two sets
of blood cultures will cost $140 and the cost of PCT is
$20 per measurement. In this cohort, using a preset
PCT cutoff value of ≤0.25 μg/l would save 40% of blood
cultures while still identifying 97% of bacteremias. Thus
the potential saving in blood culture resources is ($140
times 0.40 minus $20) $36 per patient and $20.916 for
the whole cohort of 581 patients.
Discussion
In this study, we evaluated the ability of clinical and
laboratory characteristics to predict bacteremia in adults
presenting with febrile UTI. We found that PCT dichot-
omized around 0.25 μg/l, is a robust surrogate marker
for bacteremia, whereas the actual PCT value reflects
bacterial load in the blood stream. PCT might be
applied to help guide and limit the use of blood culture
resources.
We used a PCT cutoff value of ≤0.25 μg/l after having
tested different standard cutoff values as has been advo-
cated by the manufacturer’s instructions to indicate
absence or presence of sepsis or even absence or
Table 2 Multivariate logistic regression models predicting
bacteremia in 581 patients with febrile UTI.
Multivariate OR
(95% CI)
P-value R
2
Model 1 0.145
Age >65 years 2.4 (1.5 to 3.8) <0.001
Temperature >38.6°C 2.1 (1.3 to 3.3) 0.001
Altered mental status 1.8 (0.9 to 3.5) 0.093
Heart rate >100/minute 1.7 (1.1 to 2.7) 0.015
Diabetes mellitus 1.6 (1.0 to 2.7) 0.063
Shaking chills 1.5 (1.0 to 2.3) 0.052
Antibiotic UTI treatment 1.5 (0.9 to 2.3) 0.085
Model 2 0.293
Age >65 years 1.6 (1.0 to 2.5) 0.059
Temperature >38.6°C 1.7 (1.1 to 2.7) 0.019
Altered mental status 2.0 (1.0 to 4.2) 0.054
Diabetes mellitus 1.8 (1.0 to 3.1) 0.035
PCT > 0.25 μg/l 14.7 (6.6 to 32.6) <0.001
Model 3 (univariate) 0.252
PCT > 0.25 μg/l 18.0 (8.2 to 39.5) <0.001
UTI: urinary tract infection; OR: Odds Ratio; CI: confidence interval; PCT:
procalcitonin; R
2: Nagelkerke’sR
2.
Model 1 = Clinical model including all clinical variables of Table 1 with P-value
< 0.2 in univariate analysis.
Model 2 = Model 1 + PCT > 0.25 μg/l. Model 3 = PCT > 0.25 μg/l only.
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demonstrated in lower respiratory tract infections [23].
Compared to studies regarding PCT and bacteremia in
infections other than febrile UTI, our diagnostic thresh-
old was lower resulting in a higher sensitivity and lower
specificity [17,18,24,25]. A recent study with similar
design in patients presenting with community acquired
pneumonia demonstrated highly similar findings [26]. In
that study, a PCT value ≤0.25 μg/l would allow reducing
blood cultures by 37% while still identifying 96% of bac-
teremias [26].
Using a PCT value ≤0.25 μg/l, we demonstrate a 40%
reduction of blood cultures in our study population
while still identifying 97% of bacteremias. Using PCT as
a decision rule to guide taking blood cultures in febrile
UTI would thus likely to be cost-effective. Moreover, it
might prevent false-positive blood cultures and costs of
associated medical consultations. However, other labora-
tory values that might routinely be measured in patients
presenting with febrile UTI such as C-reactive protein
(CRP) and the erythrocyte sedimentation rate (ESR)
could also be indicative for the presence of bacteremia.
In this study, CRP and ESR were measured in a subset
of ED patients when indicated by the attending physi-
cian. Both were significantly associated with bacteremia
but had very limited diagnostic ability compared to PCT
(see Additional file 1). This is like other studies that did
not recommend the use of CRP and ESR for diagnosing
bacteremia [24,25].
The clinical characteristics associated with the pre-
sence of bacteremia comprise two categories. One com-
prises clinical signs which are a result of the host’s
response to bacterial components and cytokines elicited
by the local infection and possible systemic expansion
(that is, chills, confusion, temperature >38.6°C, heart
rate >100/minute) and the other category includes host-
related risk factors for a complicated clinical course of
disease such as older age and diabetes. All these clinical
factors were found to be associated with bacteremia in
previous studies in patients with UTI [6,7,11,12]. Similar
to previous reports on smaller cohorts, we were not able
to accurately predict the presence of bacteremia based
on clinical characteristics only. Likely, this can be
explained in part by the relatively old study population
Table 3 Predictive value of different models predicting bacteremia in 581 adults with febrile UTI.
No. patients
without
risk factor (%)
Sensitivity,
%
(95% CI)
Specificity,
%
(95% CI)
NPV, %
(95% CI)
PPV, %
(95% CI)
LR +
(95% CI)
LR -
(95% CI)
Model 1
Risk factor A 271 (47) 70 (62 to 78) 52 (46 to 56) 86 (81 to 89) 30 (25 to 35) 1.45 (1.25 to 1.68) 0.58 (0.44 to 0.75)
Risk factors A, B 127 (22) 90 (83 to 94) 25 (21 to 30) 90 (83 to 94) 26 (22 to 30) 1.21 (1.12 to 1.30) 0.39 (0.23 to 0.66)
Risk factors A, B, C 112 (19) 93 (87 to 97) 23 (19 to 27) 92 (85 to 96) 26 (22 to 30) 1.21 (1.13 to 1.29) 0.30 (0.16 to 0.57)
Model 2
Risk factor B 270 (46) 68 (60 to 76) 51 (46 to 56) 85 (80 to 89) 29 (24 to 34) 1.39 (1.21 to 1.62) 0.61 (0.48 to 0.80)
Risk factors B, D 229 (39) 78 (70 to 85) 45 (40 to 49) 88 (83 to 92) 29 (25 to 34) 1.42 (1.26 to 1.61) 0.48 (0.34 to 0.67)
Risk factors P, B 140 (24) 97 (92 to 99) 30 (26 to 34) 97 (92 to 99) 29 (25 to 33) 1.39 (1.30 to 1.49) 0.10 (0.04 to 0.27)
Risk factors P, B, D 116 (20) 97 (92 to 99) 25 (21 to 29) 97 (91 to 99) 27 (23 to 32) 1.29 (1.21 to 1.37) 0.12 (0.05 to 0.33)
Model 3
PCT > 0.25 μg/l 234 (40) 95 (89 to 98) 50 (46 to 55) 97 (94 to 99) 36 (31 to 41) 1.91 (1.73 to 2.11) 0.11 (0.05 to 0.22)
NPV, negative predictive value; PPV, positive predictive value; LR+, positive likelihood ration; LR-, negative likelihood ratio; A, Age >65 years; B, Temperature
>38.6°C; C, heart rate >100/minute; D, diabetes mellitus; P, PCT > 0.25 μg/l. For Model 1 and Model 2 the corresponding sensitivity, specificity, NPV, PPV, LR+ and
LR- are calculated using a cutoff value of ≥1 risk factor.
Figure 2 Relation between procalcitonin level at presentation
with E. coli urosepsis (n = 25) and time to positivity of blood
culture.
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nesses might result in heterogeneous symptoms of bac-
teremia [27].
A relationship between PCT and TTP of the blood
cultures has indirectly been suggested in the setting of
discriminating blood contamination from bloodstream
infection due to coagulase-negative staphylococci [28].
However, to our knowledge a direct relationship
between PCT and the TTP of the blood culture in gram
negative bacteremia has not been addressed previously.
As the majority of bacteremic UTI is caused by gram
negative microorganisms, we hypothesized that the bac-
terial load likely reflects the level of free lipopolysac-
charide and thus the level of endotoxemia, which is
correlated with the PCT value [18]. The TTP of the
blood culture that depends on the rate of carbon diox-
ide production by the microorganisms can be used as a
surrogate for systemic bacterial load, and we, thus, ana-
lyzed its correlation with PCT [29]. Because the TTP
depends on the microorganism and the logistics around
blood culture obtainment, we decided to analyze this for
E. coli bacteremias of one center only [19]. We found a
significant loglinear relationship between PCT value and
TTP that supports biological plausibility between PCT
value and the bacterial load of infection. Probably a
similar phenomenon is indirectly illustrated by studies
in lower respiratory tract infection that demonstrated
that a low PCT value reflects a self-limiting disease that
does not require antibiotic treatment while higher PCT
values are associated with complicated outcome [30,31].
However, it should be emphasized that in this study low
PCT levels were not indicative of absence of urinary
tract infection. Hence, all patients included in this study
received antimicrobial treatment. Therefore, additional
studies are needed as to whether PCT might be of value
in guiding antibiotic treatment of UTI and decision
upon hospitalization as non-bacteremic patients are
likely to be good candidates for outpatient treatment. In
this respect, the results of a recent study are not pro-
mising as they do not support the use of PCT in helping
guide physicians in deciding about hospitalization in
patients with acute pyelonephritis [32]. This is in accor-
dance with a smaller study demonstrating that PCT was
not correlated with adverse outcome of acute pyelone-
phritis [33]. Interestingly, this latter study also showed
significant higher PCT levels in bacteremic patients
compared to nonbacteremic patients.
Our study has several strengths. First of all, we pro-
spectively included consecutive patients with febrile UTI
at multiple sites at primary care and ED setting. Thus,
our study population reflects the broad population of
routine clinical practice. Secondly, we were able to
achieve blood culture and PCT results in over 90% of
the study population. Furthermore, the rate of
bacteremia was 23% indicating that many patients suf-
fered the urosepsis syndrome [2]. Recommended by sep-
sis guidelines, all such patients require blood cultures
before the initiation of antibiotic treatment [16]. Yet,
using PCT ≤ 0.25 μg/l as a decision rule would have
resulted in a 40% reduction of blood culture utilization,
with 3% loss of detection of bacteremia. The relation
between PCT and TTP supports previous suggestions in
other infections that PCT may serve as a predictive bio-
marker for degree and severity of bacterial invasion.
There may, however, also be some limitations. Almost
30% of the patients did use antibiotics at the time of
presentation as fever apparently developed during treat-
ment of a nonfebrile UTI, for example, cystitis. This
may have led to false negative blood cultures and could
contribute to a relative low specificity of PCT in diag-
nosing bacteremia. However, antibiotic pretreatment for
cystitis in The Netherlands usually concerns nitrofuran-
toin, a drug that is unlikely to affect bacteremia in UTI.
Consistent herewith, pretreatment was associated with a
higher chance of bacteremia and this suggests that anti-
biotic pretreatment did not skew our results towards
negative blood cultures. Nevertheless, this still does not
exclude the possibility that the rate of bacteremia may
reflect an underestimate. Another limitation might be
the measurement of PCT values that was done after-
wards. Though the frozen storage of blood sample does
not influence its PCT value, the measurement of PCT in
routine clinical practice might be different [34]. Further-
more, when used to limit the use of blood cultures, a
quick result of PCT, preferably by a readily available
point-of-care assay, is mandatory for practical reasons.
This study might have consequences for the current
practices on EDs as implementation of a PCT strategy
likely is a cost-effective way to avoid taking blood cul-
tures with a very low chance of yielding a positive cul-
ture. Moreover, besides in febrile UTI, this also seems
to hold for patients presenting with community acquired
pneumonia [26]. Taken together, these studies suggest
that in the majority of patients presenting with febrile
illnesses at ED, being either respiratory or urinary tract
infections, medical diagnostic costs can be reduced.
However, it should be highlighted that additional valida-
tion studies are needed, as the in- and exclusion criteria
applied in this study might limit its generalizability to
other settings and special patients groups. Furthermore,
implementation studies addressing its cost-effectiveness
are needed before the widespread use of PCT guidance
on doing blood cultures in routine clinical practice can
be recommended.
Conclusions
We conclude that PCT accurately predicts the presence
of bacteremia and its bacterial load in adults with febrile
van Nieuwkoop et al. Critical Care 2010, 14:R206
http://ccforum.com/content/14/6/R206
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teremia in febrile UTI and may be used to help guide
efficient use of blood culture resources.
Key messages
￿ According to sepsis guidelines, blood cultures should
be drawn to help diagnose bacteremia in case of febrile
UTI, but the usefulness and cost-effectiveness of this
practice have been questioned.
￿ This study confirms that bacteremia in febrile UTI
can neither be predicted nor ruled out by bedside avail-
able clinical parameters.
￿ A low value (≤0.25 μg/l) of the biomarker procalcito-
nin (PCT) sufficiently rules out bacteremia in febrile
UTI.
￿ Implementation of PCT into clinical practice with
the aim to limit avoidable blood cultures is likely to be
cost effective.
￿ In case of bacteremia the level of PCT appeared to
be a marker of the bacterial load. Whether this might
have implications for the dosage and length of antibiotic
treatment awaits further studies.
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